Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Poor adherence is a common reason for treatment failure in many fields of medicine, and likely affects common psychiatric treatments as well. Members of the present study team have used Medication Event Monitoring System (MEMS®) caps effectively to objectively monitor adherence in skin disease, and have shown that they provide a much more accurate measure of adherence behavior than self-reports, pill counts, or serum drug concentrations. The present study will use MEMS® caps to measure adherence in 10 patients with depression and 10 patients with attention-deficit hyperactivity disorder (ADHD) from a student clinic population. The aims will be to show the usefulness of MEMS® caps in measuring adherence to psychiatric treatment, and gather data on typical adherence rates for depression and ADHD patients on typical treatment regimens. The data obtained will be used to inform future studies that use an intervention to improve adherence behavior and ultimately disease outcomes.
| Condition |
|---|
|
Major Depressive Disorder Attention-deficit Hyperactivity Disorder (ADHD) |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Measuring Adherence to Standard-of-Care Medication for Depression and ADHD in a College Student Population |
- Adherence to Standard-of-Care Medication for Depression or ADHD [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]Adherence to standard-of-care medication for depression or ADHD will be objectively measured using a bottle fitted with a Medication Event Monitoring System (MEMS®) cap and the percentage of prescribed doses taken will be reported as the outcome.
| Estimated Enrollment: | 20 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Depression
Ten subjects with diagnosis of major depressive disorder from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for depression.
|
|
ADHD
Ten subjects with a diagnosis of attention-deficit hyperactivity disorder (ADHD) from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for their ADHD.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Twenty male and female subjects, ten with depression and ten with ADHD, will be recruited. Subjects will be recruited from the Student Health Clinic at Wake Forest University, as we plan to assess adherence in a typical population of college students with depression or ADHD.
Inclusion Criteria:
- Any male or female, at least 18 years of age, using the Student Health Clinic, with a diagnosis of depression or ADHD.
- Written consent of participation must be given by the subject.
Exclusion Criteria:
- Subject is less than 18 years of age.
- Inability to complete all study-related visits.
- Introduction of any other prescription medication while participating in the study. (Patients who are on a stable dose of non-study-related prescription medications for at least 4 weeks prior to the study, and throughout the study period, are not excluded.)
- Female patients whose medications may be harmful during pregnancy must be on an acceptable form of birth control, otherwise they will not be eligible for participation.
Contacts and Locations| Contact: Guy K Palmes, MD | 3367162011 | gpalmes@wakehealth.edu |
| Contact: Sebastian G Kaplan, PhD | 3367164551 | sgkaplan@wakehealth.edu |
| United States, North Carolina | |
| Wake Forest University Health Sciences | Recruiting |
| Winston-Salem, North Carolina, United States, 27157 | |
| Contact: Guy K Palmes, MD 336-716-2011 gpalmes@wakehealth.edu | |
| Contact: Sebastian G Kaplan, PhD 3367164551 sgkaplan@wakehealth.edu | |
| Principal Investigator: Guy K Palmes, MD | |
| Principal Investigator: | Guy K Palmes, MD | Wake Forest University |
More Information
No publications provided
| Responsible Party: | Guy K. Palmes, M.D., Associate Professor of Psychiatry & Behavioral Medicine, Wake Forest University Baptist Medical Center |
| ClinicalTrials.gov Identifier: | NCT01430767 History of Changes |
| Other Study ID Numbers: | WFBMC-Psych-17564 |
| Study First Received: | September 6, 2011 |
| Last Updated: | September 7, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Wake Forest University Baptist Medical Center:
|
adherence |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Attention Deficit Disorder with Hyperactivity Depressive Disorder, Major Hyperkinesis Behavioral Symptoms Mood Disorders |
Mental Disorders Attention Deficit and Disruptive Behavior Disorders Mental Disorders Diagnosed in Childhood Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013